Concurrent Investment Advisors LLC Acquires 26,733 Shares of Merck & Co., Inc. $MRK

Concurrent Investment Advisors LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 10.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 280,871 shares of the company’s stock after purchasing an additional 26,733 shares during the period. Concurrent Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $36,092,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Prosperitas Financial LLC increased its holdings in Merck & Co., Inc. by 26.0% in the second quarter. Prosperitas Financial LLC now owns 2,835 shares of the company’s stock valued at $364,000 after purchasing an additional 585 shares during the period. NEOS Investment Management LLC lifted its holdings in Merck & Co., Inc. by 11.0% during the 2nd quarter. NEOS Investment Management LLC now owns 404,459 shares of the company’s stock worth $51,973,000 after buying an additional 40,020 shares during the period. High Net Worth Advisory Group LLC lifted its holdings in Merck & Co., Inc. by 2.4% during the 2nd quarter. High Net Worth Advisory Group LLC now owns 15,581 shares of the company’s stock worth $2,002,000 after buying an additional 366 shares during the period. Strengthening Families & Communities LLC grew its position in shares of Merck & Co., Inc. by 4.2% in the 2nd quarter. Strengthening Families & Communities LLC now owns 41,350 shares of the company’s stock valued at $5,314,000 after buying an additional 1,667 shares during the last quarter. Finally, Smallwood Wealth Investment Management LLC grew its position in shares of Merck & Co., Inc. by 6.2% in the 2nd quarter. Smallwood Wealth Investment Management LLC now owns 3,432 shares of the company’s stock valued at $441,000 after buying an additional 200 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the sale, the executive vice president owned 110,167 shares of the company’s stock, valued at $14,501,282.21. This trade represents a 9.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP David Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last 90 days. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $152.32 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The business has a 50-day moving average price of $134.20 and a two-hundred day moving average price of $123.33. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92. The company has a market cap of $375.80 billion, a P/E ratio of 121.86, a PEG ratio of 6.60 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Guggenheim increased their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Scotiabank raised their price target on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Fifteen research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $147.60.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.